|
Hormone dependent cancers as well as several psychiatric ailments require daily injections for periods spanning several months to years, and this is very painful for the patient.
Our depot technology uses long-acting microparticles that offer slow/sustained drug release over a month to several months, which can be given using a conventional injection. The competitor’s product involves administration using a thick hypodermic needle.
The particle size of our biodegradable polymer-based product is such that the product can be injected by normal subcutaneous or intramuscular injection.
Conventionally used solvents and diluents are used to formulate the injection, minimizing the likelihood of a reaction. No local anesthetic is required to administer this injection. This technology can be applied to the production of peptides also. A manufacturing friendly, closed and semiautomatic process has been developed to give a kilogram scale, reproducible product.
Comparable to currently marketed products is in preclinial trials, with clinical studies slated for 2008.
A GnRH analogue and somatostatin analogue will move into the subsequent stages of clinical research.
| 
Novel Drug Delivery Technologies that offer safer and more effective drug delivery.
